- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04656262
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients (METROPHOLYS)
The METROPHOLYS Study Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas Randomized, Controlled Open Label Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This phase III randomized clinical trial was designed to compare metronomic Cyclophosphamide with standard Doxorubicin for the first-line treatment of elderly cancer patients with advanced inoperable or metastatic STS:
i) ARM A (experimental): Metronomic Cyclophosphamide ii) ARM B (control): Doxorubicin up to six cycles
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Gian Luca De Salvo
- Phone Number: 0039-049-8215710
- Email: gianluca.desalvo@iov.veneto.it
Study Locations
-
-
-
Bologna, Italy, 40136
- Not yet recruiting
- Istituto Ortopedico Rizzoli IRCCS
-
Contact:
- Emanuela Palmerini, MD
-
Candiolo, Italy, 10060
- Not yet recruiting
- Fondazione del Piemonte per l'Oncologia IRCCS
-
Contact:
- Giovanni Grignani, MD
-
Meldola, Italy, 47014
- Recruiting
- IRST Romagnolo IRCCS
-
Contact:
- Toni Ibrahim, MD
-
Milano, Italy, 20133
- Not yet recruiting
- Istituto Nazionale Tumori IRCCS
-
Contact:
- Silvia Stracchiotti, MD
-
Padova, Italy, 35128
- Recruiting
- Istituto Oncologico Veneto IRCCS
-
Contact:
- Antonella Brunello, PhD
-
Palermo, Italy, 90127
- Not yet recruiting
- AOU Policlinico Giaccone Palermo
-
Contact:
- Giuseppe Badalamenti, MD
-
Prato, Italy, 59100
- Not yet recruiting
- Ospedale Misericordia e Dolce
-
Contact:
- Giacomo GI Baldi, MD
-
Roma, Italy, 00128
- Recruiting
- Policlinico Universitario Campus Biomedico
-
Contact:
- Bruno Vincenzi, MD
-
Roma, Italy, 00144
- Not yet recruiting
- IFO - Istituto Regina Elena
-
Torino, Italy, 10153
- Not yet recruiting
- Presidio Sanitario Humanitas - Gradenico
-
Contact:
- Alessandro Comandone, MD
-
Verona, Italy, 37134
- Recruiting
- AOUI Policlinico Borgo Roma
-
Contact:
- Sara Cingarlini, MD
-
-
BO
-
Bologna, BO, Italy, 40138
- Recruiting
- Policlinico Sant'Orsola Malpighi
-
Contact:
- Margherita Nannini, MD
-
-
MI
-
Rozzano, MI, Italy, 20089
- Recruiting
- Istituto Clinico Humanitas
-
Contact:
- Andrea Marrari, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients may be included in the study only if they meet all the following criteria:
- Histologically proven diagnosis of soft tissue sarcoma.
- Advanced unresectable or metastatic soft tissue sarcoma not previously treated with chemotherapy for metastatic disease.
- At least one measurable lesion according to RECIST1.1 criteria.
- Availability of a tumor sample (primary and/or metastatic sites).
- Age ≥ 70 years (70-75 years if UNFIT at G8; >75 independent of G8 score)
- ECOG PS 0-2.
- Life expectancy of at least 12 weeks.
- Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hgb ≥ 9 g/dl.
- Adequate hepatic function, defined as: Total bilirubin ≤ 1.5 time the upper-normal limits (ULN) of the normal values, ASAT (SGOT) and/or ALAT (SGPT) ≤ 2.5 x ULN (or <5 x ULN in case of liver metastases)
- Alkaline phosphatase ≤ 2.5 x ULN (or <5 x ULN in case of liver metastases).
- Creatinine clearance ≥ 30 mL/min.
- Normal cardiac function, with left ventricular ejection fraction (LVEF) ≥50%.
- Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator
- Geriatric assessment by means of G8 screening tool and CRASH score.
- Will and ability to comply with the protocol.
- Written informed consent to study participation.
Exclusion Criteria:
Patients will be excluded from the study for any of the following reasons:
- Previous treatment for metastatic disease.
- Previous (neo) adjuvant chemotherapy with anthracyclines.
- Radiotherapy to any site within 4 weeks before the study.
- Untreated brain metastases or spinal cord compression or primary brain tumors.
- Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration.
- Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), serious cardiac arrhythmia requiring medication.
- Treatment with any investigational drug within 30 days prior to enrollment or 2 investigational agent half-lives (whichever is longer)
- Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ.
- Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
- Known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs.
- Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies.
- Sexually active males unwilling to practice contraception during the study and until 6 months after the last trial treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metronomic cyclophosphamide
Cyclophosphamide 50 mg daily per os continuously; Patients will be visited for re-cycling every three weeks.
Metronomic cyclophosphamide will be taken in the morning along with a full glass of water.
|
Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
Other Names:
|
Active Comparator: Doxorubicin
Doxorubicin 60 mg/mq i.v. in 10 minutes, day 1; to be repeated every three weeks up to a maximum of 6 cycles.
|
Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to treatment failure
Time Frame: From date of randomization until the date of treatment discontinuation due to disease progression, toxicity leading to treatment discontinuation, or death, whichever occurs first, assessed up to 12 months
|
Progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment. Toxicity is assessed according to NCI-CTCAE criteria v. 4.03 |
From date of randomization until the date of treatment discontinuation due to disease progression, toxicity leading to treatment discontinuation, or death, whichever occurs first, assessed up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free Survival
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
Progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
Overall survival
Time Frame: Time from randomization to the date of death due to any cause or last follow up assessed up to 12 months
|
Overall Survival is defined as the time from date of randomization to the date of death due to any cause
|
Time from randomization to the date of death due to any cause or last follow up assessed up to 12 months
|
Overall Toxicity Rate
Time Frame: From signing IC until 30 days after last study treatment
|
Toxicities will be recorded, classified, graded and managed according to NCI CTCAE v. 4.03.
|
From signing IC until 30 days after last study treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Antonella Brunello, Istituto Oncologico Veneto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Doxorubicin
Other Study ID Numbers
- IOV-2018-STS-METROPHOLYS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma Adult
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue SarcomaUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)WithdrawnRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue SarcomaUnited States, Canada
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupTerminatedRecurrent Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 | Stage II Adult Soft Tissue Sarcoma AJCC v7 | Stage III Adult Soft Tissue Sarcoma AJCC v7United States
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue SarcomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Liposarcoma | Adult Synovial SarcomaUnited States
-
Northwestern UniversityAVEO Pharmaceuticals, Inc.CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue SarcomaUnited States
Clinical Trials on Cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Centre Oscar LambretCompleted
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted